Primary Central Nervous System Lymphoma: Molecular Pathogenesis and Advances in Treatment

Area of Science:

• Oncology
• Hematology
• Genetics

Background:

• Primary central nervous system lymphoma (PCNSL) is an aggressive extranodal non-Hodgkin lymphoma.
• PCNSL is characterized by specific biological features, aggressive progression, and poor patient outcomes.
• Identifying genetic alterations and molecular pathways is crucial for developing targeted therapies and improving prognosis.

Purpose of the Study:

• To review genetic and epigenetic alterations in PCNSL pathogenesis.
• To summarize and evaluate the efficacy of current PCNSL treatments.
• To propose novel therapeutic agents for recurrent and relapsed PCNSL.

Main Methods:

• Literature review of genetic and epigenetic alterations in PCNSL.
• Summary and evaluation of treatment modalities including surgery, chemotherapy, radiotherapy, and stem cell transplantation.
• Analysis of recent clinical research for potential new agents.

Main Results:

• Various genetic and epigenetic alterations implicated in PCNSL pathogenesis were identified.
• The efficacy of established treatments like chemotherapy, radiotherapy, and stem cell transplantation was evaluated.
• Potential new therapeutic agents for relapsed/recurrent PCNSL were proposed based on recent clinical findings.

Conclusions:

• Understanding PCNSL genetic landscape is key to targeted therapy development.
• Current treatment strategies offer varying efficacy, highlighting the need for novel approaches.
• Further research into new agents is essential for improving outcomes in recurrent and relapsed PCNSL.